Thrombocytopenias: A clinical point of view

Blood Transfusion

Volumn 7, Issue 2, 2009, Pages 75-85

  Veneri, Dino ^a   Franchini, Massimo ^b   Randon, Federica ^a   Nichele, Ilaria ^a   Pizzolo, Giovanni ^a   Ambrosetti, Achille ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; DICOUMAROL; DIURETIC AGENT; HEPARIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LOW MOLECULAR WEIGHT HEPARIN; QUINIDINE; STEROID; SULFONAMIDE; TICLOPIDINE;

AMEGAKARYOCYTIC THROMBOCYTOPENIA; AUTOIMMUNE THROMBOCYTOPENIA; AUTOSOMAL DOMINANT DISORDER; BERNARD SOULIER DISEASE; CLINICAL FEATURE; DIGEORGE SYNDROME; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MEGADOSE; FANCONI ANEMIA; GANGRENE; GENE MUTATION; GLUCOSE METABOLISM; GRAY THROMBOCYTE SYNDROME; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MAY HEGGLIN ANOMALY; MEDITERRANEAN MACROTHROMBOCYTOPENIA; MICROTHROMBUS; MONTREAL PLATELET SYNDROME; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; REVIEW; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VON WILLEBRAND DISEASE; WISKOTT ALDRICH SYNDROME; X LINKED THROMBOCYTOPENIA;

ALGORITHMS; BLOOD PLATELETS; CELL SIZE; CELL SURVIVAL; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; HEMORRHAGE; HUMANS; LYMPHATIC DISEASES; SPLENOMEGALY; SYNDROME; THROMBOCYTOPENIA;

EID: 66349123064     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2008.0012-08     Document Type: Review

References (85)

1. Ruggeri M, Fortuna S, Rodeghiero F. Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. Haematologica 2008; 93: 98-103.
2. Diz-Küçükkaya R, Hacihanefioglu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001; 98: 1760-1764
3. Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 2004; 30: 273-283 (Pubitemid 39037620)
4. Mant MJ, Doery JC, Gauldie J, Sims H. Pseudothrombocytopenia due to platelet aggregation and degranulation in blood collected in EDTA. Scand J Haematol 1975; 15: 161-170
5. Peters M, Heyderman RS, Klein NJ. Platelet satellitism. N Engl J Med 1998; 339: 131-132
6. Behrens WE. Mediterranean macrothrombocytopenia. Blood 1975; 46: 199-208.
7. Savoia A, Balduini CL, Savino M, et al. Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome. Blood 2001; 97: 1330-1335 (Pubitemid 32183756)
8. Kunishima S, Saito H. Congenital macrothrombocytopenias. Blood Rev 2006; 20: 11-21. (Pubitemid 43295745)
9. Balduini CL, Savoia A. Inherited thrombocytopenias: molecular mechanisms. Semin Thromb Hemost 2004; 30: 513-523 (Pubitemid 39426384)
10. So CC, Wong KF. May-Hegglin anomaly. Br J Haematol 2003; 120: 373. (Pubitemid 36241491)
11. Greinacher A, Nieuwenhuis HK, White JG. Sebastian platelet syndrome: a new variant of hereditary macrothrombocytopenia with leukocyte inclusions. Blut 1990; 61: 282-288
12. Peterson LC, Rao KA, Crosson JT, White JG. Fechtner syndrome - a variant of Alport's syndrome with leukocyte inclusions and macrothrombocytopenia. Blood 1985; 65: 397-406. (Pubitemid 15163578)
13. Epstein CJ, Sahud MA, Piel CF, et al. Hereditary macrothrombocytopathia, nephritis and deafness. Am J Med 1972; 75: 299-310.
14. Crawfurd MA. Alport's syndrome. J Med Genet 1988; 25: 632-637
15. Pecci A, Panza E, Pujol-Moix N, et al. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 2008;29:409-417
16. Franchini M, Lippi G. The role of von Willebrand factor in hemorrhagic and thrombotic disorders. Crit Rev Clin Lab Sci 2007; 44: 115-149 (Pubitemid 46272637)
17. Miller JL, Castella A. Platelet-type von Willebrand's disease: characterization of a new bleeding disorder. Blood 1982; 60: 790-794
18. Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1988; 91: 4397-4418 (Pubitemid 28270285)
19. Yu C, Niakan KK, Matsushita M, et al. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood 2002; 100: 2040-2045 (Pubitemid 35001235)
20. Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 23: 166-175 (Pubitemid 29455388)
21. Okita JR, Frojmovic MM, Kristopeit S, et al. Montreal platelet syndrome: a defect in calcium-activated neutral proteinase (calpain). Blood 1989; 74: 715-721 (Pubitemid 19208815)
22. Franchini M, Lippi G, Veneri D, et al. Inherited platelet disorders. Clin Chim Acta 2008; 387: 1-8. (Pubitemid 350050924)
23. Muroi K, Amemiya Y, Miwa A, et al. Long-term bone marrow failure accompanied by skin pigmentation. Int J Hematol 1991; 54: 281-287
24. King S, Germeshausen M, Strauss G, et al. Br J Haematol 2005; 131: 636-644
25. Rengan R, Ochs HD. Molecular biology of the Wiskott-Aldrich syndrome. Rev Immunogenet 2000; 2: 243-255
26. Orange JS, Stone KD, Turvey SE, Krewsky K. The Wiskott-Aldrich syndrome. Cell Mol Life Sci 2004; 61: 2361-2385 (Pubitemid 39382027)
27. Homans AC, Cohen JL, Mazur EM. Defective megakaryocytopoiesis in the syndrome of thrombocytopenia with absent radii. Br J Hematol 1989; 71: 277-280
28. Thompson AA, Nguyen LT. Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated with HOXA11 mutation. Nat Genet 2000; 26: 397-398
29. Van Geet C, Devriendt K, Eyskens B, et al. Velocardiofacial syndrome patients with a heterozygous chromosome 22q11 deletion have giant platelets. Pediatr Res 1998; 44: 607-611 (Pubitemid 28447351)
30. Kadikoylu G, Yavasoglu I, Bolaman Z, Senturk T. Platelet parameters in women with iron deficiency anemia. J Natl Med Assoc 2006; 98: 398-402. (Pubitemid 43352530)
31. Yenicesu I, Yetgin S, OzyŸrek E, Aslan D. Virus-associated immune thrombocytopenic purpura in childhood. Pediatr Hematol Oncol 2002; 19: 433-437
32. Budman DR, Steimberg AD. Hematologic aspects of systemic lupus erythematosus. Ann Int Med 1977; 86: 220-229
33. Michalska Z, Stalke P, Witczak-Malinowska K, et al. Autoimmune reactions in HBV and HCV. Med Sci Monit 2001; 7: 175-180
34. Bahner J, Kearns K, Coutinho S, et al. Infection of human marrow stroma by human immunodeficency virus-1 (HIV-1) is both required and sufficient for HIV-1-induced hematopoietic suppression in vitro: demonstration by gene modification of primary human stroma. Blood 1997; 90: 1787-1789 (Pubitemid 27377288)
35. Veneri D, Franchini M, Gottardi M, et al. Efficacy of Helicobacter pylori eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. Haematologica 2002; 87: 1177-1179 (Pubitemid 35397776)
36. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40. (Pubitemid 26230668)
37. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999; 94: 909-913 (Pubitemid 29361821)
38. Rodeghiero F. Idiopathic thrombocytopenic purpura: an old disease revisited in the era of evidence-based medicine. Haematologica 2003; 88: 1081-1087 (Pubitemid 37362537)
39. Woerner SJ, Abilgard CF, French BN. Intracranial hemorrhage in children with idiopathic thrombocytopenic purpura. Pediatrics 1981; 67: 453-460 (Pubitemid 11061312)
40. Provan D, Norfolk D, Bolton-Maggs P, et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and pregnancy. Br J Hematol 2003; 120: 574-596
41. Raife TJ, Olson JD, Lentz SR. Platelet antibody testing in idiopathic thrombocytopenic purpura. Blood 1997; 89: 1112-1114 (Pubitemid 27121308)
42. Beardsley DS. ITP in the 21st Century. Hematology (Am Soc Hematol Educ Program) 2006; 402-407
43. Liebman HA, Stasi R. Secondary immune thrombocytopenic purpura. Curr Opin Hematol 2007; 14: 557-573 (Pubitemid 47457647)
44. Galli M, Barbui T. Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests. Semin Thromb Hemost 2005; 31: 17-24. (Pubitemid 40262133)
45. Vlachoyiannopoulos PG, Samarcos M, Sikara M, Tsiligros P. Antiphospholipid antibodies: laboratory and pathogenetic aspects. Critical Rev Clin Lab Sci 2007; 44: 271-338. (Pubitemid 46525176)
46. Asherson RA. A "primary" antiphospholipid syndrome? J Rheumatol 1988; 15: 1742-1746
47. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996: 100: 530-536 (Pubitemid 26170477)
48. Lockshin MD, Druzin ML, Goei S, et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985; 313: 152-156 (Pubitemid 15047457)
49. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
50. Galli M, Daldossi M, Barbui T. Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1994; 71: 571-575 (Pubitemid 24132953)
51. Gruel Y, Rupin A, Watier H, et al. Anticardiolipin antibodies in heparin-associated thrombocytopenia. Thromb Res 1992; 67: 601-606
52. Hulstein JJ, Lenting PJ, de Laat B, et al. beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 2007; 110: 1483-1491 (Pubitemid 47443963)
53. Diz-Kucukkaya R, Hacihanefio?lu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001; 98: 1760-1764
54. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357: 580-587 (Pubitemid 47236283)
55. George JN, Raskob GE, Shah SR, et al. Drug induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129: 886-890 (Pubitemid 28549817)
56. von der Bone AE, Pegels JG, van der Stadt RJ, et al. Thrombocytopenia associated with gold therapy: a drug-induced autoimmune disease? Br J Haematol 1986; 63: 509-516
57. Franchini M. Heparin-induced thrombocytopenia: an update. Thromb J 2005; 3: 14. (Pubitemid 41548701)
58. Warketin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Hematol 2003; 121: 535-555 (Pubitemid 36645375)
59. Warkentin TE. Heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2007; 21: 589-607.
60. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996; 92: 494-497 (Pubitemid 26042948)
61. Warketin TE. Think of HIT. Hematology (Am Soc Hematol Educ Program) 2006; 408-414
62. Comunale ME, van Cott EM. Heparin-induced thrombocytopenia. Int Anesthesiol Clin 2004; 42: 27-43. (Pubitemid 38963093)
63. Poley S, Mempel W. Laboratory diagnosis of heparin-induced thrombocytopenia: advantages of a functional flow cytometric test in comparison to the heparin-induced platelet-activation test. Eur J Haematol 2001; 66: 253-262 (Pubitemid 32436740)
64. Warkentin TE, Elavathil LJ, Hayward CP, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804-812 (Pubitemid 27465548)
65. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70: 554-561
66. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 1999; 100: 587-593 (Pubitemid 29379746)
67. Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846-851 (Pubitemid 30616845)
68. Lewis BE, Wallis DE, Berkowitz SD, for the ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-1843
69. Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 2003; 101: 31-37 (Pubitemid 36025883)
70. Schultz AS, Urban J, Gessler P, et al. Anaemia, thrombocytopenia and coagulopathy due to occult diffuse infantile haemangiomatosis of spleen and pancreas. Eur J Pediatr 1999; 158: 379-383 (Pubitemid 29198192)
71. Nabhan C, Kwaan HC. Current concepts in the diagnosis and management of thrombotic thrombocytopenic purpura. Hematol Oncol Clin North Am 2003; 17: 177-199 (Pubitemid 36206069)
72. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
73. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-1935 (Pubitemid 43872694)
74. Moake JL. Haemolytic-uraemic syndrome: basic science. Lancet 1994; 343: 393-397 (Pubitemid 24049560)
75. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med 1998; 339: 1578-1584 (Pubitemid 28536132)
76. Veyradier A, Obert B, Houllier A, et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathy: a study of 111 cases. Blood 2001; 98: 1765-1772
77. Sadler JE, Moske JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program) 2004; 407-423
78. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. New Engl J Med 1991; 325: 393-397
79. Okajima K, Sakamoto Y, Uchiba M. Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: a study of 204 cases. Am J Hematol 2000; 65: 215-222
80. Toh CH, Downey C. Back to the future: testing in disseminated intravascular coagulation. Blood Coagul Fibrinol 2005; 16: 535-542 (Pubitemid 41658971)
81. McCrae KR, Bussel JB, Mannucci PM, et al. Platelets: an update on diagnosis and management of thrombocytopenic disorders. Hematology (Am Soc Hematol Educ Program) 2001; 282-305.
82. Veneri D, Franchini M, Raffaelli R, et al. Idiopathic thrombocytopenic purpura in pregnancy: analysis of 43 consecutive cases followed at a single Italian institution. Ann Hematol 2006; 85: 552-554 (Pubitemid 44283102)
83. Cines DB, Bussel JB, McMillan RB, Zehnder JL. Congenital and acquired thrombocytopenia. Hematology (Am Soc Hematol Educ Program) 2004; 390-406.
84. Dreyfus M, Kaplan C, Verdy E, et al. Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group. Blood 1997;89:4402-4406 (Pubitemid 27260250)
85. Bassler D, Greinacher A, Okascharoen C, et al. A systematic review and survey of the management of unexpected neonatal alloimmune thrombocytopenia. Transfusion. 2008; 48: 92-98